A groundbreaking study presented at ASCO reveals that AstraZeneca’s experimental pill camizestrant, when used based on blood test results, can halve the risk of breast cancer progression or death—potentially reshaping treatment for patients with hormone receptor-positive, HER2-negative breast cancer
AstraZeneca’s experimental drug camizestrant significantly reduced the risk of disease progression or death in patients with advanced hormone receptor-positive, HER2-negative breast cancer by 56%, when prescribed based on early blood test results rather than visible tumor growth, experts announced Sunday at the American Society of Clinical Oncology (ASCO) meeting in Chicago.
The international trial marks a major shift in cancer treatment strategy by using liquid biopsy—a blood test that detects ESR1 gene mutations indicating early resistance to standard hormone therapies. Camizestrant, a selective estrogen receptor degrader (SERD), was shown to be effective in patients with early treatment resistance, even before tumors could be detected via imaging.
“This is going to be very impactful for our patients,” said Dr. Hope Rugo, head of breast medical oncology at City of Hope, California. “We’re staying ahead of the curve rather than reacting after the disease has already progressed,” added Dr. Eleonora Teplinsky, another ASCO expert.
The Phase 3 clinical trial involved 3,256 women, all previously treated with aromatase inhibitors and CDK4/6 inhibitors like Pfizer’s Ibrance or Novartis’ Kisqali. Among them, 315 women who developed ESR1 mutations were selected for a randomized trial. Those who switched to camizestrant plus CDK4/6 inhibitors experienced a median 16 months of progression-free survival compared to 9.2 months in the control group that continued standard therapy.
Camizestrant is not yet FDA-approved, but based on these findings, it may soon be adopted as part of a new treatment paradigm for early intervention in breast cancer progression.
AstraZeneca CEO Pascal Soriot acknowledged that integrating liquid biopsy into routine practice would initially be challenging but emphasized it as the future of cancer care.
In a separate announcement at the same ASCO meeting, another AstraZeneca drug, Imfinzi (durvalumab), showed promise in improving outcomes for early-stage stomach and esophageal cancer patients. When added to chemotherapy before and after surgery, Imfinzi reduced the risk of cancer recurrence, progression, or death by 29%.
Both sets of results were published in the New England Journal of Medicine and are expected to have lasting implications for the future of oncology.
Read next
17:13
U.S. strikes on Iran
Azerbaijan’s Foreign Ministry on Saturday voiced deep concern over the escalating tensions following the United States’ military strikes on Iranian nuclear facilities, calling on all sides to prioritize diplomacy over confrontation.
16:11
Bold and Brilliant
The Pentagon concluded a high-stakes press briefing Saturday afternoon following the U.S. strikes on Iran’s nuclear facilities, outlining the scale and success of the mission while stressing the door remains open to diplomacy.
15:53
Türkiye
Türkiye has voiced strong concern following the United States’ strikes on Iranian nuclear facilities, warning that the action could dangerously escalate the conflict and trigger a global crisis.
14:00
oil price
Global investors are bracing for significant market turmoil when trading reopens, with analysts predicting a sharp spike in oil prices and a flight to safe-haven assets following the United States' announcement of military strikes against three Iranian nuclear facilities.
13:55
"Red Line" crossed
Iran’s top diplomat on Sunday issued a stark condemnation of the United States following overnight military strikes on Iranian nuclear facilities, declaring that Washington had crossed a "very big red line" and would be held "fully responsible" for the consequences.
What is your opinion on this topic?
Leave the first comment